TX2-121-1
Based on 1 Customer Validation
TX2-121-1 is a bifunctional hydrophobic tag Her3 degrader and also a Her3 inhibitor with an IC50 of 49 nM. TX2-121-1 covalently binds to Cys721 of Her3, induces Her3 degradation via the Hsp70/Hsp90-assisted proteasomal pathway, interferes with the heterodimerization of Her3 with Her2/c-Met, and attenuates downstream Erk/Akt signaling, thereby inhibiting Her3-dependent cancer cell growth. TX2-121-1 can be used for the research of non-small cell lung cancer, ovarian cancer and Her3-driven breast cancer.
(Pink: HER3 ligand (HY-164988); Blue: HyT ligand (HY-N2427); Black: linker).
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1603845-42-6
- Fòrmula: C42H52N8O3
- Peso molecular:716.91
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas EGFR
More
Actividad biológica
Descripciòn
IC50 & Target
[1]|
HER3 49 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| PC-9 | EC50 |
0.87 μM
|
Induction of preferential death of Her3-dependent PC9 GR4 cells via enhanced inhibition of Her3-dependent signals, measured by cell-based viability assay.
Induction of preferential death of Her3-dependent PC9 GR4 cells via enhanced inhibition of Her3-dependent signals, measured by cell-based viability assay.
|
34488823 |
| PC-9 | EC50 |
0.9 μM
|
Antiproliferative activity against PC9 GR4 lung cancer cells expressing wild-type Her3 assessed as reduction in cell viability incubated for 3 days by CellTiter-Glo® Luminescent Assay.
Antiproliferative activity against PC9 GR4 lung cancer cells expressing wild-type Her3 assessed as reduction in cell viability incubated for 3 days by CellTiter-Glo® Luminescent Assay.
|
25326665 |
| PC-9 | EC50 |
5.5 μM
|
Antiproliferative activity against PC9 GR4 lung cancer cells expressing Her3 C721S mutant assessed as reduction in cell viability incubated for 3 days by CellTiter-Glo® Luminescent Assay.
Antiproliferative activity against PC9 GR4 lung cancer cells expressing Her3 C721S mutant assessed as reduction in cell viability incubated for 3 days by CellTiter-Glo® Luminescent Assay.
|
25326665 |
| PC-9 | EC50 |
0.8 μM
|
Antiproliferative activity against Her3-dependent PC9 GR4 cancer cells assessed as reduction in cell viability incubated for 3 days by CellTiter-Glo® Luminescent Assay.
Antiproliferative activity against Her3-dependent PC9 GR4 cancer cells assessed as reduction in cell viability incubated for 3 days by CellTiter-Glo® Luminescent Assay.
|
25326665 |
| HCC827 | EC50 |
0.8 μM
|
Antiproliferative activity against Her3-dependent HCC827 GR6 cancer cells assessed as reduction in cell viability incubated for 3 days by CellTiter-Glo® Luminescent Assay.
Antiproliferative activity against Her3-dependent HCC827 GR6 cancer cells assessed as reduction in cell viability incubated for 3 days by CellTiter-Glo® Luminescent Assay.
|
25326665 |
| OVCAR-8 | EC50 |
0.8 μM
|
Antiproliferative activity against Her3-dependent Ovcar8 cancer cells assessed as reduction in cell viability incubated for 3 days by CellTiter-Glo® Luminescent Assay.
Antiproliferative activity against Her3-dependent Ovcar8 cancer cells assessed as reduction in cell viability incubated for 3 days by CellTiter-Glo® Luminescent Assay.
|
25326665 |
| PC-9 | EC50 |
0.8-1.4 μM
|
Antiproliferative activity against human PC9 GR4 cells.
Antiproliferative activity against human PC9 GR4 cells.
|
37535706 |
| HCC827 | EC50 |
0.8-1.4 μM
|
Antiproliferative activity against human HCC827 GR6 cells.
Antiproliferative activity against human HCC827 GR6 cells.
|
37535706 |
| OVCAR-8 | EC50 |
0.8-1.4 μM
|
Antiproliferative activity against human Ovcar8 cells.
Antiproliferative activity against human Ovcar8 cells.
|
37535706 |
In Vitro
TX2-121-1 (compound 2e) binds to purified Her3 with an IC50 of 49 nM[1].
TX2-121-1 (2 μM) acts as a selective binder for Her3 in live cells[1].
TX2-121-1 (1-5 μM; 12 h) induces partial degradation of Her3 in PC9 GR4 cells[1].
TX2-121-1 (0.5-2 μM; 12 h) reduces the phosphorylation levels of Erk and Akt, downstream effectors of Her3, in serum-starved PC9 GR4 cells stimulated with neuregulin[1].
TX2-121-1 (1 μM; 6 h) reduces the heterodimerization of Her3 with Her2 and c-Met in PC9 GR4 cells[1].
TX2-121-1 (3 h) potently binds to the purified human Her3 kinase domain with an IC50 of 49.2 nM, and exhibits Her3-centered kinome selectivity, showing no direct inhibitory activity against EGFR or Her2 enzymes at concentrations below 10 μM[3].
TX2-121-1 (1 μM; 6 h) inhibits the heterodimerization of Her3 with Her2 and c-Met in PC9 GR4 lung cancer cells, and exhibits stronger inhibitory activity against Her2/Her3 dimers[3].
TX2-121-1 potently binds to purified Her3 protein, with an IC50 value of 49.2 nM[4].
TX2-121-1 (500 nM) covalently binds to and degrades endogenously expressed ErbB3 in ErbB3-dependent cell lines, thereby inhibiting downstream signal transduction and cell proliferation[5].
TX2-121-1 inhibits HER3-dependent signaling pathways, induces partial degradation of HER3, and disrupts the heterodimerization of HER3 with HER2 and c-Met in cultured cells[6].
TX2-121-1 inhibits the proliferation of PC9 GR4 cells, and its potency is approximately 7-fold that of the non-covalent control TX2-135-2[1].
TX2-121-1 selectively induces PC9 GR4 cell death by enhancing the inhibition of Her3-dependent signaling, with an EC50 of 0.87 μM[2].
TX2-121-1-mediated intracellular Her3 degradation is enhanced upon combined treatment with the chaperone inhibitors 116-9e or Tanespimycin (17-AAG) (HY-10211)[2].
TX2-121-1 (0.5-2 μM; 12 h) induces partial degradation of Her3 in starved PC9 GR4 lung cancer cells and inhibits NRG-stimulated phosphorylation of Erk and Akt[3].
TX2-121-1 (administered consecutively for 3 days) inhibits the proliferation of PC9 GR4 lung cancer cells expressing wild-type Her3, with an EC50 of 0.9 μM; in cells expressing the Her3C721S mutant, the activity of this compound decreases (EC50 = 5.5 μM), indicating that its targeting activity depends on covalent binding to Cys721[3].
TX2-121-1 (administered for 3 consecutive days) selectively inhibits the proliferation of Her3-dependent cancer cell lines (PC9 GR4, HCC827 GR6, Ovcar8), with EC50 values ranging from 0.8 to 1.4 μM[3].
Degradation of Her3 in PC9 GR4 lung cancer cells induced by TX2-121-1 (0.5 μM) is enhanced by inhibition of Hsp70 or Hsp90, and is dependent on the proteasome[3].
TX2-121-1 (2 μM; 12 h) induces partial degradation of Her3 in starved PC9 GR4 cells, thereby inhibiting the downstream Her2 and c-Met signaling pathways[4].
TX2-121-1 inhibits the proliferation of Her3-dependent PC9 GR4, HCC827 GR6 and Ovcar8 cell lines, with EC50 values ranging from 0.8 to 1.4 μM[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:PC9 GR4 cells
-
Concentration:1, 5 μM
-
Incubation Time:12 h
-
Result:Induced partial degradation of Her3 at both tested concentrations.
Showed more evident degradation compared to other adamantane conjugates and the non-adamantane control TX2-120-1.
-
Cell Line:serum-starved PC9 GR4 cells
-
Concentration:0.5, 2 μM
-
Incubation Time:12 h
-
Result:Attenuated phosphorylation of the downstream Her3 effectors Erk and Akt after NRG stimulation.
Outperformed non-covalent or non-adamantane control compounds, which did not show this effect.
-
Cell Line:starved PC9 GR4 (EGFR E746_A750/T790M) lung cancer cells
-
Concentration:0.5, 2 μM
-
Incubation Time:12 h
-
Result:Induced partial degradation of Her3 protein.
Inhibited the phosphorylation of Erk and Akt following NRG stimulation.
-
Cell Line:PC9 GR4 (EGFR E746_A750/T790M) lung cancer cells
-
Concentration:1 μM
-
Incubation Time:6 h
-
Result:Effectively reduced the association of Her3 with both Her2 and c-Met.
Showed a greater inhibitory effect on Her2/Her3 heterodimerization than on c-Met/Her3 heterodimerization.
Chemical Information
-
No. CAS 1603845-42-6
-
Peso molecular 716.91
-
Fòrmula C42H52N8O3
-
SMILES
C[C@@H](C(NCCN1CCC(N2C3=NC=NC(N)=C3C(C(C=C4)=CC(NC(C=C)=O)=C4OC5=CC=CC=C5)=N2)CC1)=O)CCC6(C[C@H](C7)C8)C[C@H]8C[C@H]7C6
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Pureza y Documentación
Referencias
[1]. Lim SM, et al. Development of small molecules targeting the pseudokinase Her3. Bioorganic & medicinal chemistry letters. 2015 Aug 15;25(16):3382-9. [Content Brief]
[3]. Xie T, et al. Pharmacological targeting of the pseudokinase Her3. Nature chemical biology. 2014 Dec;10(12):1006-12. [Content Brief]
[4]. Xie S, et al. Small-Molecule Hydrophobic Tagging: A Promising Strategy of Druglike Technology for Targeted Protein Degradation. Journal of medicinal chemistry. 2023 Aug 24;66(16):10917-10933. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)